News

advocacy

Statement of Lymphoma Research Foundation on Access to Treatment

Policymakers in Washington, DC, and state capitols are considering measures to address the cost of health care, including prescription drugs, and to address insurance adequacy issues. As debate on these initiatives intensifies, we urge that policymakers consider the needs of people with lymphoma and lymphoma survivors.

Statement Of Lymphoma Research On Access To Quality Cancer Care In Response To Dobbs V. Jackson Women’s Health Organization

Statement of Lymphoma Research on Access to Quality Cancer Care In Response to Dobbs V. Jackson Women’s Health Organization The Lymphoma Research Foundation (LRF) is dedicated to ensuring that lymphoma patients have access to quality care that is evidence-based, medically…

lymphoma

What Lymphoma Patients Need to Know About Current Treatments for COVID-19

As of mid-2022, there are a number of treatments for COVID-19 that have been either approved by the FDA or have been authorized for emergency use (EUA).

Lymphoma Research Foundation Names Sarah Quinlan Chief Program Officer

Lymphoma Research Foundation Names Sarah Quinlan Chief Program Officer The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization dedicated exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach…

diffuse large b-cell lymphoma, lymphoma

U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (BREYANZI) for Large B-Cell Lymphoma

The U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma On June 24, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved the use of lisocabtagene maraleucel (liso-cel, Breyanzi), a chimeric antigen receptor…

follicular lymphoma, lymphoma

U.S. Food and Drug Administration Approves CAR T Cell Therapy for Follicular Lymphoma

FDA announced it has approved the use of tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Meet the 2022 Career Development Award, Postdoctoral Fellowship, and Follicular Lymphoma Priority Research Grantees

The Lymphoma Scientific Research Mentoring Program (LSRMP) is a first-of-its-kind education and mentoring program for junior scientists who wish to focus on lymphoma clinical and laboratory/translational research.

follicular lymphoma, lymphoma

Advocating for Answers

After 20 years of living with lymphoma, Lois Rosenblum knows firsthand the importance of a strong support system and advocating for your health. Following an initial diagnosis of follicular lymphoma in 2002 and several disease transformations since then, she’s passionate about supporting the work that the Lymphoma Research Foundation (LRF) does to power cutting-edge research to treat and defeat lymphoma.

lymphoma, Mantle Cell Lymphoma

Where Are They Now? Carla Casulo, MD

Dr. Carla Casulo is a medical oncologist at the University of Rochester Medical Center.

Lymphoma Research Foundation’s 2022 North American Educational Forum on Lymphoma To be Held Virtually

LRF announced today that its premier patient education program, the 2022 North American Educational Forum on Lymphoma, will be held virtually from Friday, October 28th to Sunday, October 30th.

Subscribe to Our Emails. Get lymphoma and CLL resources and updates.